Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Clinicians should be alert to this possibility when evaluating patients presenting with unexplained hypoglycemia who report GLP-1 agonist use, especially if obtained from non-pharmacy sources or online
Regulatory Awareness : Retatrutide is currently investigational and not FDA-approved
Br J Nutr 93(6):845851 Alvarez E, Martnez MD, Roncero I, Chowen JA, Garca-Cuartero B, Gispert JD et al (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem
In clinical trials where a GLP-1 RA was added to background basal insulin, a general 20% basal insulin reduction in all patients or a 20% reduction in patients with an A1C 8.0%, the GLP-1 RA can be reasonably initiated without a reduction in the basal insulin dose for many patients
